🔎 Trials Near Me

Domov › Steatotična bolezen jeter › Texas

Klinične študije za Steatotična bolezen jeter v Texas

20 študij za Steatotična bolezen jeter išče udeležence na lokacijah v Texas.

Mesta v Texas

Uradno besedilo študije (angleško)

A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

  • GSK Investigational Site, Arlington
  • GSK Investigational Site, Austin
  • GSK Investigational Site, Bellaire
  • in še 5
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07704892

A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

  • GSK Investigational Site, Arlington
  • GSK Investigational Site, Austin
  • GSK Investigational Site, Bellaire
  • in še 4
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07701993

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

  • American Research Corporation, Austin
  • Advanced Medical Trials, Georgetown
  • American Research Corporation at The Texas Liver Institute, San Antonio
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07527910

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

  • American Research Corporation, Austin
  • Pinnacle Clinical Research - Austin, Austin
  • Methodist Dallas Medical Center, Dallas
  • in še 5
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05519475

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  • IMA Clinical Research Austin, Austin
  • American Research Corporation, Austin
  • Pinnacle Clinical Research, Austin
  • in še 26
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07165028

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

  • Akero Clinical Study Site, Arlington
  • Akero Clinical Study Site, Austin
  • Akero Clinical Study Site, Austin
  • in še 28
Vključevanje udeležencevFaza 3
Starost 18–80 · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT06528314

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  • GSK Investigational Site, Austin
  • GSK Investigational Site, Austin
  • GSK Investigational Site, Brownsville
  • in še 12
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07221188

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

  • Pinnacle Clinical Research, Austin
  • Bellaire Clinical Research, Bellaire
  • South Texas Research Institute (STRI) - Brownsville, Brownsville
  • in še 14
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07288138

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

  • 89bio Clinical Study Site, Amarillo
  • 89bio Clinical Study Site, Austin
  • 89bio Clinical Study Site, Austin
  • in še 30
Vključevanje udeležencevFaza 3
Starost 18–80 · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06318169

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

  • 89bio Clinical Study Site, Amarillo
  • 89bio Clinical Study Site, Austin
  • 89bio Clinical Study Site, Austin
  • in še 21
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06419374

Quantifying Hepatic Mitochondrial Fluxes in Humans

  • Texas Diabetes Institute - University Health System, San Antonio
  • University of Texas Health Science Center at San Antonio, San Antonio
Vključevanje udeležencevFaza 4
Starost 18–80 · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT05305287

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

  • GSK Investigational Site, Arlington
  • GSK Investigational Site, Austin
  • GSK Investigational Site, Dallas
  • in še 4
Vključevanje udeležencevFaza 2
Starost 18–70 · Vsi spoli · Posodobljeno 3. avg. 2026 · NCT06613698

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

  • GSK Investigational Site, Arlington
  • GSK Investigational Site, Austin
  • GSK Investigational Site, Austin
  • in še 16
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 27. jul. 2026 · NCT07221227

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

  • GSK Investigational Site, Austin
  • GSK Investigational Site, Austin
  • GSK Investigational Site, Austin
  • in še 10
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 8. jul. 2026 · NCT06920043

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

  • GSK Investigational Site, San Antonio
Vključevanje udeležencevFaza 1
Starost 18–70 · Vsi spoli · Posodobljeno 9. jun. 2026 · NCT07358546

Evaluating the Pharmacokinetics and Safety of Miricorilant

  • Site# 433, San Antonio
Vključevanje udeležencevFaza 1
Starost 18–75 · Vsi spoli · Posodobljeno 26. maj 2026 · NCT07553663

Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population

  • Methodist Dallas Medical Center, Dallas
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 13. maj 2026 · NCT06225193

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  • Pioneer Research Solutions, Houston
Vključevanje udeležencevFaza 1/2Vabljeni zdravi prostovoljci
Starost 18–75 · Vsi spoli · Posodobljeno 16. apr. 2026 · NCT05648214

NAFLD Clinical Care Pathway

  • Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 18 in več · Vsi spoli · Posodobljeno 14. nov. 2025 · NCT06671886

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

  • First Surgical Hospital, Bellaire
  • Endeavor Clinical Trials, San Antonio
Vključevanje udeležencevOpazovalna študija
Starost 18–75 · Vsi spoli · Posodobljeno 14. avg. 2025 · NCT07122700

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.